80 The A allele is also strongly associated with T2D,81 linking over-nutrition/obesity with its metabolic complications. Studies in NAFLD/NASH will now be

of interest. The A allele contains the first EGFR inhibiton intron of fat mass and obesity-associated gene [FTO] and another gene, fantom (FTM). FTO and FTM are expressed in the hypothalamus and suppressed by fasting, implicating roles in appetite suppression.82 Like Alms1, FTM is a structural component of basal bodies, indicating the potential relevance to cilial function. In support of multiple gene interactions, Loos et al. found summation in the effects of FTO and MC4R with fat mass and risk of obesity.77 Likewise, in Han Cabozantinib cell line Chinese, the combined effects of three genes, one in the estrogen receptor, two in peroxisome-proliferation activator receptor-gamma (PPAR-γ), was greater than any individual gene; collectively, they conferred

> 5-fold (OR 5.3) increased risk of severe obesity (Table 3).83 Robust studies linking individual genes to development of fatty liver have been lacking until recently. The patatin-like phosphatase family consists of nine genes, five collectively designated as the adiponutrin family (PNPLA1-5).84,85 The proteins are expressed in WAT and liver, and their action is believed to complement hormone-sensitive lipase (HSL), a key enzyme involved with adipocyte lipolysis.84 Genetic variations in HSL have been previously linked to obesity, glucose intolerance and dyslipidemia—all relevant

to NASH.86 In 2008, Romeo et al. used GWAS to identify a before SNP, rs738409, within PNPLA3 that was strongly associated with increased hepatic fat content.87 In subjects drawn from the multiethnic Dallas Heart Study mentioned earlier,70PNPLA3 (rs738409 G allele) was present with highest frequency in Hispanics, intermediate in whites and lowest in blacks.87 Hepatic fat content was two-fold greater for G allele homozygotes than for non-carriers of this allele, accounting for all the ethnic differences in MRS-determined hepatic triglyceride content. Another PNPLA3 allele (rs6006460 [T]) was associated with lower hepatic fat content and is most common in African Americans, the group with lowest prevalence of NAFLD.70 The association between PNPLA3 (rs738409 G allele) and hepatic fat content has been confirmed in Finnish and Argentinian cohorts,88,89 and is independent of age, gender, BMI and insulin resistance. In data presented at a recent meeting, PNPLA3 polymorphisms were associated with fibrotic severity of NASH.90,91 Environmental factors, in particular dietary composition, undoubtedly play a role in facilitating the imbalance between energy intake and consumption that underlies the present pandemic of over-nutrition.

Obviously, the mRNA expression of Oatp1b2 was nearly abolished in the Oatp1b2-null mice. Ntcp and Oatp2b1 find more mRNA were approximately 20% higher in the Oatp1b2-null mice than in WT mice. Oatp1a4 also tended to be higher in Oatp1b2-null mice, but it was not statistically significant. The middle panel of Fig. 6 shows that there were no changes in the expression of basolateral efflux transporters Abca1, multidrug resistance–associated protein (Mrp) 3, or Mrp6, but the mRNA expression of Mrp4 and organic solute transporter (Ost) α was about 40%-50%

lower in the Oatp1b2-null mice. As the bottom panel of Fig. 6 indicates, there were no differences in mRNA expression of canalicular transporters in the two genotypes, except Abcg5, which was 35% higher in Oatp1b2-null mice. Because there were changes in the disposition of unconjugated BAs, we quantified the mRNA expression of major BA synthetic enzymes in both the classical and alternative pathways. Surprisingly, the mRNA expression

of Cyp7a1, the rate-limiting enzyme in the classical pathway, was 70% lower in Oatp1b2-null mice. The alternative pathway of bile acid synthesis was not altered in Oatp1b2-null mice (Fig. 7, top panel). To better understand the decrease of Cyp7a1 expression in Oatp1b2-null mice, the mRNA expression of Cyp7a1 regulatory ICG-001 factors was quantified in the liver and ileum. As shown in the middle and bottom panels of Fig. 7, the mRNAs of Thiamet G fibroblast growth factor receptor 4 (Fgfr4, 20%) and SHP (86%) were higher in the livers of Oatp1b2-null mice than in WT mice. The mRNA expression of fibroblast growth factor 15 (Fgf15)

in the ileum tended to be higher in Oatp1b2-null mice. The last decade has seen a resurgence of BA research. BAs not only participate in the elimination of cholesterol, activation of pancreatic enzymes, and emulsification of lipid droplets, they are also important signaling molecules that help to control cholesterol, glucose, lipid, and energy homeostasis. BAs also regulate their own homeostasis.12 With regard to BA homeostasis, the body is economic, in that the enterocytes effectively take up most of the luminal BAs and transport them back into the blood, and only 5% of biliary excreted BAs vanish with the feces each day.13, 14 It is important to properly regulate the synthesis and enterohepatic recirculation of BAs because of their detergent properties and signaling roles. BA homeostasis is regulated by the orchestration of BA synthesis in the liver, and the uptake and efflux transporters in the liver and terminal ileum. In the intestinal lumen, the conjugated BAs are deconjugated and a portion is metabolized to secondary BAs (e.g., DCA, LCA) by intestinal bacteria. The unconjugated and conjugated BAs are reabsorbed in the terminal ileum mainly by apical sodium-dependent bile acid transporter (Asbt) and delivered to the liver through the portal vein.

5 points (A) and net worsening of 2.5 points or more (B). Results: Before the second TACE, 43 patients (31%) had a score ART ≥2.5 and 96 patients a score ART between 0 and 1.5. The median overall survival of our population was 28 months (22,

34). There was a significant difference between the two groups A and B regarding median survival (p < 0.0001), with a median of 34 months A (28–38) and 13 months B (10–16). There was a significant difference between the two groups regarding the value of AFP, Child-Pugh score, BCLC classification, encapsulated character or infiltrating tumor, the presence of a segmental portal vein thrombosis. There was a significant difference in response rate after TACE and with median time to progression. But there was no difference between the two groups regarding patient age, BMI, underlying liver disease, the presence of diabetes, the circumstances of discovery, the presence of buy Roxadustat significant Esophageal varices, the existence of a previous treatment. Conclusion: This study confirms the prognostic value of ART score calculated before the second TACE in a different population, in better condition with more often viral disease. Elevated transaminases frequently observed in viral diseases do not interfere on the reliability of the score. Key Word(s): 1. chemoembolization; 2. HCC; 3. BCLC classification; 4. ART score; Presenting Author: ADHOUTE XAVIER Additional Authors: CASTELLANI PAUL, POL BERNARD,

PERRIER HERVÉ, CAMPANILE MANUELA, WENDT ASTRID, BEAURAIN PATRICK, MONNET OLIVIER, PENARANDA GUILLAUME, RAOUL JEAN LUC, BOURLIERE MARC Corresponding Author: ADHOUTE XAVIER Affiliations: Fondation Saint-Joseph; Alphabio Laboratory; PF2341066 Institut Paoli Calmettes Objective: Primary liver cancers are dominated by hepatocellular carcinoma (HCC), which mainly develops on chronic liver disease (HBV,

HCV, alcohol, metabolic syndrome). Intrahepatic cholangiocarcinoma Cyclin-dependent kinase 3 (ICC) are the second most common primary liver malignancy, they arise from bile duct epithelium within the liver. Their incidence is increasing in the West, Oceania, United States. Besides the classical etiologies (intrahepatic cholelithiasis, cholangitis, parasitosis), new risk factors are suspected: cirrhosis, chronic hepatitis (HCV, HBV), metabolic syndrome, type II diabetes. Aim of the study: risk factors associated with Intrahepatic cholangiocarcinoma. Presentation, course and treatments. Comparative study with HCC. Methods: Material and method: During the period 01/2007 – 12/2012, 405 consecutive patients were admitted to our unit for the management of Primary liver tumors. HCC diagnosis was based on EASL criteria. Patients without cirrhosis had tumor biopsy. Etiology of liver disease was systematically sought: HBV, HCV, iron load, auto-immune markers and metabolic syndrome. Results: The diagnosis of ICC was based on histology in 100% of cases vs 18% for HCC (EASL radiological criteria) (p < .0001). ICC accounted for 8% (n = 32) of the pts.

Using just the high values for a given year, Schell (2000) compiled an isotopic time series for the Bering Sea. The study raised questions on two grounds. First, the shifts Schell (2000) detected may relate more to changes in whale migration or diet than to any shift in δ13C values of Bering Sea phytoplankton. Second, as noted by Cullen et al. (2001), phytoplankton δ13C values should have dropped over the last 60 yr due to the rise in atmospheric CO2, because fossil fuel combustion pumps 13C-depleted PLX-4720 ic50 carbon into global ecosystems, and because high aqueous [CO2] leads to increased photosynthetic

fractionation. The concern about the “reality” of the drop in North Pacific δ13C values has been addressed through study of additional time series from other species, including pinnipeds and sea birds (Hirons et al. 2001a, Hobson et al. 2004b). The most controlled study in temporal, spatial, and taxonomic http://www.selleckchem.com/products/Everolimus(RAD001).html terms is Newsome

et al. (2007b). The authors sampled dentin from the third dental annulus of male northern fur seals from a single rookery on Saint Paul Island in the Pribilofs, with intensive sampling (∼5 samples/yr) from 1948 to 2000, as well as a few scattered samples from the early 20th century. Mean annual δ13C values declined by approximately 1.1‰ from 1948 to 2000 (Fig. 5A), while long-term mean annual δ15N values did not change significantly (Fig. 5B). The relatively small but significant long-term drop in δ13C values can be entirely explained by the anthropogenic changes in surface ocean carbon reservoirs

noted by Cullen et al. (2001) and need not entail a decline in primary productivity as posited by Schell (2000, 2001). Finally, both δ13C and δ15N time series showed low amplitude oscillations with a frequency of 20–25 yr that may be related to shifts in climatic and/or oceanographic conditions resulting from the Pacific Decadal Oscillation. The Pleistocene epoch, beginning approximately 1.8 mya, was marked by many dramatic climatic shifts, the waxing and waning of massive continental http://www.selleck.co.jp/products/wnt-c59-c59.html ice sheets, and large (∼120 m), rapid fluctuations in sea level. The changes must have had profound impacts on marine mammal populations. For example, at the last glacial maximum, just 20,000 yr ago, the Pribilof islands (where most northern fur seals breed today) were not islands at all, but rather were uplands at the edge of a vast low lying plain extending from Siberia to Alaska that was inhabited by a host of large carnivores (lions, sabertooths, gray wolves, brown bears, short-faced bears) (Manley 2002, Guthrie 2004). For the last 10,000 yr (the Holocene), climatic variations have been more subdued, but not absent.

[6] Headache disorders other than migraine did not feature in GBD2000 at all; for these disorders, at that time, dependable evidence was lacking everywhere. Filling this evidence

gap has been a priority of the Global Campaign in its first years.[7] As a result, GBD2010 has been much better informed and built on much sounder foundations than its predecessor (we return to this point later). GBD2010 was not a simple compound screening assay update of GBD2000, but a complete rerun: an entirely new world survey. Working with many partners, the Global Campaign against Headache being one, it took from the world literature all the epidemiological evidence pertaining to burdensome diseases, assessed it for quality and derived

from it, for each of 21 world regions, best age-related estimates of prevalence. Like GBD2000, it measured burden in disability-adjusted life years, separated into the two components of YLDs and years of life lost to early mortality; for headache, only the former are relevant. New disability weights (DWs) were assigned to each disease: lay descriptions of the various health states that were predictable sequelae of each disease were fed into a web-based worldwide consultation, which conducted an iterative series of comparisons, one health state with another. For migraine and tension-type headache (TTH), descriptions were agreed of average cases and three health states of each: ictal (during attacks), interictal (between attacks), and the health state DMXAA solubility dmso associated with medication-overuse headache (MOH), which was considered a potential complication of either. Information from published studies on frequency and duration of migraine or TTH episodes was pooled in order to estimate the average proportions of time (pT) spent in the ictal as opposed to interictal state. MOH was assumed to be continuous (pT = 1) heptaminol when present. YLDs for each of these states were then derived as products of prevalence,

pT, and DW, and for each disease as the sum of YLDs for each health state. Data were included from 84 studies of migraine in 43 countries in 16 of the 21 world regions, and from 45 studies of TTH in 34 countries in 13 world regions. TTH (estimated global prevalence 20.1%) and migraine (14.7%) ranked, respectively, as second and third most common diseases in the world (behind dental caries) in both males and females. For migraine, the estimated proportion of time spent in the ictal state was 5.3%, and the DW assigned to migraine episodes was 0.433 (43.3% disability). On the basis of ictal disability alone, migraine was ranked seventh highest among specific causes of disability globally (responsible for 2.

The aim of this study was to determine the associations of readily available demographic, clinical, and laboratory variables with the diagnosis of NASH and its key histological features, and determine the ability of these variables to predict the severity of nonalcoholic fatty liver www.selleckchem.com/HDAC.html disease (NAFLD). A total of 1266 adults were enrolled in NASH CRN studies between October 2004 and February 2008, of whom 1101 had available liver histology. The median age was 50 years; 82% were white and 12% Hispanic. The median body mass index was 33 kg/m2; 49% had hypertension and 31% had type 2 diabetes. On liver biopsy, 57% were judged to have definite NASH and 31%

bridging fibrosis or cirrhosis. Using Selleckchem Stem Cell Compound Library data from the 698 patients with liver biopsies within 6 months of clinical data, patients with definite NASH were more likely to be female and have diabetes, higher levels of aspartate and alanine aminotransferases, alkaline phosphatase, gamma glutamyl transpeptidase, and homeostasis model assessment of insulin resistance (HOMA-IR). Progressive models for predicting histological diagnoses performed modestly for predicting steatohepatitis or ballooning

(area under receiver operating characteristic curves [AUROC] ranged from 0.70-0.79), and better for advanced fibrosis (AUROC 0.73-0.85). Conclusion: Readily available clinical and laboratory variables can predict advanced fibrosis in adults with NAFLD, but additional information is needed to reliably predict the presence and severity of NASH. Prospective studies of this well-characterized population and associated tissue bank samples offer a unique opportunity to better understand the cause and natural history of NAFLD and develop find more more precise means for noninvasive diagnosis. (HEPATOLOGY 2010) Nonalcoholic fatty liver disease (NAFLD) affects 10%-30% of the general U.S. population and can progress to significant fibrosis and cirrhosis.1 When nonalcoholic steatohepatitis (NASH) is present, the 5-year and 10-year survivals are estimated

at 67% and 59%, respectively.2 The presence of NASH and early fibrosis is currently established only by liver biopsy; noninvasively determining who has NASH and who is at risk for progressing to cirrhosis remains challenging.3 Serum aminotransferases are routinely measured to detect liver disease, but their specificity and sensitivity for NASH, fibrosis, or cirrhosis is low4 and the results may vary considerably over time5, 6 and among laboratories.7 The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) was initiated by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in 2002 to conduct multicenter, collaborative studies on the etiology, contributing factors, natural history, complications, and treatment of NASH.

The aim of this study was to determine the associations of readily available demographic, clinical, and laboratory variables with the diagnosis of NASH and its key histological features, and determine the ability of these variables to predict the severity of nonalcoholic fatty liver Cabozantinib disease (NAFLD). A total of 1266 adults were enrolled in NASH CRN studies between October 2004 and February 2008, of whom 1101 had available liver histology. The median age was 50 years; 82% were white and 12% Hispanic. The median body mass index was 33 kg/m2; 49% had hypertension and 31% had type 2 diabetes. On liver biopsy, 57% were judged to have definite NASH and 31%

bridging fibrosis or cirrhosis. Using Deforolimus cost data from the 698 patients with liver biopsies within 6 months of clinical data, patients with definite NASH were more likely to be female and have diabetes, higher levels of aspartate and alanine aminotransferases, alkaline phosphatase, gamma glutamyl transpeptidase, and homeostasis model assessment of insulin resistance (HOMA-IR). Progressive models for predicting histological diagnoses performed modestly for predicting steatohepatitis or ballooning

(area under receiver operating characteristic curves [AUROC] ranged from 0.70-0.79), and better for advanced fibrosis (AUROC 0.73-0.85). Conclusion: Readily available clinical and laboratory variables can predict advanced fibrosis in adults with NAFLD, but additional information is needed to reliably predict the presence and severity of NASH. Prospective studies of this well-characterized population and associated tissue bank samples offer a unique opportunity to better understand the cause and natural history of NAFLD and develop Tideglusib more precise means for noninvasive diagnosis. (HEPATOLOGY 2010) Nonalcoholic fatty liver disease (NAFLD) affects 10%-30% of the general U.S. population and can progress to significant fibrosis and cirrhosis.1 When nonalcoholic steatohepatitis (NASH) is present, the 5-year and 10-year survivals are estimated

at 67% and 59%, respectively.2 The presence of NASH and early fibrosis is currently established only by liver biopsy; noninvasively determining who has NASH and who is at risk for progressing to cirrhosis remains challenging.3 Serum aminotransferases are routinely measured to detect liver disease, but their specificity and sensitivity for NASH, fibrosis, or cirrhosis is low4 and the results may vary considerably over time5, 6 and among laboratories.7 The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) was initiated by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in 2002 to conduct multicenter, collaborative studies on the etiology, contributing factors, natural history, complications, and treatment of NASH.

Key Word(s): 1. Urea Breath Test; 2. Klacid resistance; 3. H.pylori eradication; 4. triple therapy; Presenting Author: HWONG RUEY LEOW Additional Authors: THERESAWAN CHEN YAP, AHMAD NAJIB AZMI, MUN Selleck LDE225 FAI LOKE, JAMUNARANI VADIVELU,

KHEAN LEE GOH Corresponding Author: HWONG RUEY LEOW Affiliations: Univeristy of Malaya; University of Malaya; Univeristy of Malaya; Univeristy of Malaya Objective: H. pylori infection rate is on the decline worldwide. This is particularly so amongst children and young adults where H. pylori has virtually disappeared in some populations. Although an endoscopy based time trend study from our institution has shown a marked decline in H. pylori infection, there has been no recent studies on the prevalence of H. pylori in a young Malaysian population. Our objective is to determine the frequency of H. pylori infection and their ethnic distribution in young healthy volunteers in Malaysia. Methods: Consecutive young healthy students of the University of Malaya, Kuala Lumpur were recruited for the study. The diagnosis of H. pylori infection was determined by a validated 13C Urea Breath Test. Results: As part

of an on-going study on young healthy Malaysian adults, 447 subjects were recruited. Mean age was 22.31 ± 2.26. 13C urea breath tests were positive in 40 out of 447 volunteers giving rise NVP-BKM120 a prevalence rate of 8.9%. Eight (3.8%) of 209 Malay, Fourteen (8.5%) of 164 Chinese and eighteen (24.3%) of 74 Indian had H.pylori infection. The difference between three ethnic groups were statistically significant. (p values < 0.001). Twenty eight (9.7%) of 290 female and Edoxaban twelve (7.6%) of 157 male were 13C urea breath test positive (p values = 0.477). Conclusion: Low prevalence of H. pylori infection observed in all volunteers. The high H. pylori prevalence amongst Indians

and Chinese compared to Malays have been well shown in previous studies. However, over time, the prevalence rates in Chinese appeared to have declined dramatically nevertheless prevalence rates in Indians remains highest among the three ethnic groups. We await analysis on a larger sample population to confirm our preliminary findings described here. Key Word(s): 1. H.pylori Prevalence; 2. Multiethnicity; 3. Urea Breath Test; 4. Young Adults; Presenting Author: HWONG RUEY LEOW Additional Authors: XINSHENG TEH, MUN FAI LOKE, JAMUNARANI VADIVELU, KHEAN LEE GOH Corresponding Author: HWONG RUEY LEOW Affiliations: University of Malaya Objective: Antibiotic resistance decreases success of Helicobacter pylori. (H. pylori) eradication and therefore the primary or background resistance to various commonly used antibiotics is crucially important in our choice of treatment regimens. In a previous study in our local Malaysian population, resistance to clarithromycin and levofloxacin was shown to be zero. Our objective is to monitor the prevalence of H.

Available information on preclinical toxicology studies with PEGylated drugs did not show any PEG-related toxicities for PEGASYS® and Mircera®. In toxicity studies with Cimzia® in cynomolgus monkeys and rats conducted

with high doses of the PEGylated protein, the only PEG-related finding was vacuolation mainly in macrophages and after chronic dosing. This vacuolation did not result in functional http://www.selleckchem.com/products/chir-99021-ct99021-hcl.html changes in the animals. No PEG-related effects have been reported in clinical studies with Cimzia®. Vacuolation of macrophages and some other cell types at high PEG doses was also reported for some PEGylated proteins including PEGylated haemoglobin [13, 17, 18, 22, 23]. No changes in other tissues have been reported. The larger PEG molecules do not penetrate into tissue to the extent as PEG molecules smaller than 20 kDa [37, 38]. Therefore, it can be assumed that large PEG molecules linked to a large protein, such as FVIII, will remain in circulation until FVIII is removed through the protein-related

removal mechanisms thought to be mainly in the liver. Thus, the penetration of large PEG or PEGylated rFVIII into tissues, such as brain, can be assumed to be negligible. This is supported by the toxicology studies with the PEGylated proteins and/or with PEG alone where no indication of vacuolation of neuronal cells or microglia (derived from the same lineage as macrophages) has been observed in any of the studies. BMN 673 concentration The 60 kDa PEG moiety in BAY 94–9027 did not show any toxicity when assessed in acute and repeat administration toxicity studies, up to the highest dose tested of 210 mg kg−1 in the acute and 11 mg kg−1 in the 4 weeks toxicity study. The large safety margins Urease of the clinical dose of PEG for Cimzia®, PEGASYS® and the expected clinical dose of BAY 94–9027 to the observed vacuolation

in cells of the RES system in rats and monkeys seen only with Cimzia® (Fig. 3) suggests that long-term administration of 60 kDa PEGylated rFVIII could be a safe option. Several key points can be extracted from the experiments with 60 kDa PEG and the review of the literature on safety of high molecular weight PEG. The toxicity of a PEGylated protein is usually the same or lower than the un-PEGylated protein and the toxicity seen is related to the action of the protein moiety, not the PEG [12, 13]. The removal of the PEGylated protein from circulation is driven by mechanisms specific to the protein [12, 13], and PEGylated proteins can have reduced immunogenicity when compared to their un-PEGylated protein [4, 5, 13]. Polyethylene glycol molecules, given at low doses as in most therapeutic proteins, can be removed by the kidney and liver with low organ accumulation [33, 38].

Available information on preclinical toxicology studies with PEGylated drugs did not show any PEG-related toxicities for PEGASYS® and Mircera®. In toxicity studies with Cimzia® in cynomolgus monkeys and rats conducted

with high doses of the PEGylated protein, the only PEG-related finding was vacuolation mainly in macrophages and after chronic dosing. This vacuolation did not result in functional BMS-354825 mw changes in the animals. No PEG-related effects have been reported in clinical studies with Cimzia®. Vacuolation of macrophages and some other cell types at high PEG doses was also reported for some PEGylated proteins including PEGylated haemoglobin [13, 17, 18, 22, 23]. No changes in other tissues have been reported. The larger PEG molecules do not penetrate into tissue to the extent as PEG molecules smaller than 20 kDa [37, 38]. Therefore, it can be assumed that large PEG molecules linked to a large protein, such as FVIII, will remain in circulation until FVIII is removed through the protein-related

removal mechanisms thought to be mainly in the liver. Thus, the penetration of large PEG or PEGylated rFVIII into tissues, such as brain, can be assumed to be negligible. This is supported by the toxicology studies with the PEGylated proteins and/or with PEG alone where no indication of vacuolation of neuronal cells or microglia (derived from the same lineage as macrophages) has been observed in any of the studies. FDA-approved Drug Library manufacturer The 60 kDa PEG moiety in BAY 94–9027 did not show any toxicity when assessed in acute and repeat administration toxicity studies, up to the highest dose tested of 210 mg kg−1 in the acute and 11 mg kg−1 in the 4 weeks toxicity study. The large safety margins for of the clinical dose of PEG for Cimzia®, PEGASYS® and the expected clinical dose of BAY 94–9027 to the observed vacuolation

in cells of the RES system in rats and monkeys seen only with Cimzia® (Fig. 3) suggests that long-term administration of 60 kDa PEGylated rFVIII could be a safe option. Several key points can be extracted from the experiments with 60 kDa PEG and the review of the literature on safety of high molecular weight PEG. The toxicity of a PEGylated protein is usually the same or lower than the un-PEGylated protein and the toxicity seen is related to the action of the protein moiety, not the PEG [12, 13]. The removal of the PEGylated protein from circulation is driven by mechanisms specific to the protein [12, 13], and PEGylated proteins can have reduced immunogenicity when compared to their un-PEGylated protein [4, 5, 13]. Polyethylene glycol molecules, given at low doses as in most therapeutic proteins, can be removed by the kidney and liver with low organ accumulation [33, 38].